Exploring G Protein-Coupled Receptors (GPCRs) Ligand Space via Cheminformatics Approaches: Impact on Rational Drug Design
Open accessThe DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.
Abstract
The primary goal of rational drug discovery is the identification of selective ligands which act on single or multiple drug targets to achieve the desired clinical outcome through the exploration of total chemical space. To identify such desired compounds, computational approaches are necessary in predicting their drug-like properties. G Protein-Coupled Receptors (GPCRs) represent one of the largest and most important integral membrane protein families. These receptors serve as increasingly attractive drug targets due to their relevance in the treatment of various diseases, such as inflammatory disorders, metabolic imbalances, cardiac disorders, cancer, monogenic disorders, etc. In the last decade, multitudes of three-dimensional (3D) structures were solved for diverse GPCRs, thus referring to this period as the ‘golden age for GPCR structural biology.’ Moreover, accumulation of data about the chemical properties of GPCR ligands has garnered much interest towards the exploration of GPCR chemical space. Due to the steady increase in the structural, ligand, and functional data of GPCRs, several cheminformatics approaches have been implemented in its drug discovery pipeline. In this review, we mainly focus on the cheminformatics-based paradigms in GPCR drug discovery. We provide a comprehensive view on the ligand– and structure-based cheminformatics approaches which are best illustrated via GPCR case studies. Furthermore, an appropriate combination of ligand-based knowledge with structure-based ones i.e., integrated approach, which is emerging as a promising strategy for cheminformatics-based GPCR drug design is also discussed.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Trott, O., & Olson, A. J. (2010) · Journal of Computational Chemistry · doi:10.1002/jcc.21334 · Cited by 38,412
Development and validation of a genetic algorithm for flexible docking 1 1Edited by F. E. Cohen
Jones, G., Willett, P., Glen, R. C., Leach, A. R., & Taylor, R. (1997) · Journal of Molecular Biology · doi:10.1006/jmbi.1996.0897 · Cited by 6,763
Crystal Structure of Rhodopsin: A G Protein-Coupled Receptor
Palczewski, K., Kumasaka, T., Hori, T., Behnke, C. A., Motoshima, H., Fox, B. A., Trong, I. L., Teller, D. C., Okada, T., Stenkamp, R. E., et al. (2000) · Science · doi:10.1126/science.289.5480.739 · Cited by 5,637
Crystal structure of the β2 adrenergic receptor–Gs protein complex
Rasmussen, S. G. F., DeVree, B. T., Zou, Y., Kruse, A. C., Chung, K. Y., Kobilka, T. S., Thian, F. S., Chae, P. S., Pardon, E., Calinski, D., et al. (2011) · Nature · doi:10.1038/nature10361 · Cited by 3,009 · cited 3×
“Oligomeric complex structures of bRho coupled to G-protein peptide (Rho/G α CT) (Scheerer et al., 2008), human Rho coupled to visual arrestins (Kang et al., 2015; Zhou et al., 2017), β 2 AR coupled to Gs-protein (Rasmussen et al., 2011) and β - arrestin 1 (Shukla et al., 2014), A 2A adenosine receptor (A 2A AR) in com…”
BackgroundG Protein-Coupled Receptors as Targets for Approved Drugs: How Many Targets and How Many Drugs?
Sriram, K., & Insel, P. A. (2018) · Molecular Pharmacology · doi:10.1124/mol.117.111062 · Cited by 1,258
Crystal structure of opsin in its G-protein-interacting conformation
Scheerer, P., Park, J. H., Hildebrand, P. W., Kim, Y. J., Krauß, N., Choe, H.-W., Hofmann, K. P., & Ernst, O. P. (2008) · Nature · doi:10.1038/nature07330 · Cited by 1,059 · cited 2×
“Oligomeric complex structures of bRho coupled to G-protein peptide (Rho/GαCT) (Scheerer et al., 2008), human Rho coupled to visual arrestins (Kang et al.”
BackgroundSelf-citationReymond, J.-L. (2015) · Accounts of Chemical Research · doi:10.1021/ar500432k · Cited by 720 · cited 2×
“In the nineteenth century, chemical space exploration was initiated as a counting game to estimate its size (Reymond, 2015).”
BackgroundDeWire, S. M., Yamashita, D. S., Rominger, D. H., Liu, G., Cowan, C. L., Graczyk, T. M., Chen, X.-T., Pitis, P. M., Gotchev, D., Yuan, C., et al. (2013) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.112.201616 · Cited by 647 · cited 2×
“…biased ligands include lysergic acid diethylamide (LSD) (Wacker et al., 2017b), a well-known hallucinogen which appears to display bias toward β - arrestin signaling, and synthetic opioids TRV-130 ( DeWire et al., 2013) and PZM-21 (Manglik et al., 2016), which are biased toward G protein signaling.”
BackgroundHow Ligands Illuminate GPCR Molecular Pharmacology
Wacker, D., Stevens, R. C., & Roth, B. L. (2017) · Cell · doi:10.1016/j.cell.2017.07.009 · Cited by 560 · cited 5×
“Discovery of ligands that modulate a target’s activity has contributed largely to the understanding of both physiological and pathological processes (Wacker et al., 2017a).”
BackgroundInfluentialTrust, but Verify II: A Practical Guide to Chemogenomics Data Curation
Fourches, D., Muratov, E., & Tropsha, A. (2016) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.6b00129 · Cited by 294 · cited 1×
“Several recent articles (Fourches et al., 2010, 2016; Williams and Ekins, 2011; Williams et al., 2012) have discussed this topic at length and how it can have a negative effect on model development and performance.”
BackgroundDOGS: Reaction-Driven de novo Design of Bioactive Compounds
Hartenfeller, M., Zettl, H., Walter, M., Rupp, M., Reisen, F., Proschak, E., Weggen, S., Stark, H., & Schneider, G. (2012) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1002380 · Cited by 251 · cited 1×
“To further improve selectivity and increase the scaffold diversity, de novo design software DOGS (Hartenfeller et al., 2012) and FDA-approved drug molecule structures were utilized to produce NCEs.”
MethodLapinsh, M., Prusis, P., Gutcaits, A., Lundstedt, T., & Wikberg, J. E. S. (2001) · Biochimica et Biophysica Acta (BBA) - General Subjects · doi:10.1016/s0304-4165(00)00187-2 · Cited by 134
Luo, M., Wang, X. S., Roth, B. L., Golbraikh, A., & Tropsha, A. (2014) · Journal of Chemical Information and Modeling · doi:10.1021/ci400460q · Cited by 37
Cited by
Molecular Dynamics Simulations in Drug Discovery and Pharmaceutical Development
Salo-Ahen, O. M. H., Alanko, I., Bhadane, R., Bonvin, A. M. J. J., Honorato, R. V., Hossain, S., Juffer, A. H., Kabedev, A., Lahtela-Kakkonen, M., Larsen, A. S., et al. (2020) · Processes · doi:10.3390/pr9010071 · Cited by 659
G protein-coupled receptors: structure- and function-based drug discovery
Yang, D., Zhou, Q., Labroska, V., Qin, S., Darbalaei, S., Wu, Y., Yuliantie, E., Xie, L., Tao, H., Cheng, J., et al. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-020-00435-w · Cited by 632
Qiu, Y., Hou, Y., Gohel, D., Zhou, Y., Xu, J., Bykova, M., Yang, Y., Leverenz, J. B., Pieper, A. A., Nussinov, R., et al. (2024) · Cell Reports · doi:10.1016/j.celrep.2024.114128 · Cited by 40
GPR75: an exciting new target in metabolic syndrome and related disorders
Murtaza, B., Asghar, F., & Patoli, D. (2022) · Biochimie · doi:10.1016/j.biochi.2022.01.005 · Cited by 18
GPCR molecular dynamics forecasting using recurrent neural networks
López-Correa, J. M., König, C., & Vellido, A. (2023) · Scientific Reports · doi:10.1038/s41598-023-48346-4 · Cited by 16
Metadata
- Authors
- Basith, S., Cui, M., Macalino, S. J. Y., Park, J., Clavio, N. A. B., Kang, S., & Choi, S.
- Venue
- Frontiers in Pharmacology
- Publisher
- Frontiers Media SA
- Published
- 2018-03-09
- Volume
- 9
- Pages
- 128-128
- ISSN
- 1663-9812 (ISSN-L)
- OpenAlex
- W2792913776
- Cited by
- 142
- References
- 13
- FWCI
- 9.41
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.